Blueprint Medicines Corp (BPMC) — Cash Flow-to-Debt Ratio
Blueprint Medicines Corp (BPMC) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2025, meaning its operating cash flow of $-54.48 Million could theoretically repay 0% of its total liabilities ($853.47 Million) in one year. See BPMC free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Blueprint Medicines Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Blueprint Medicines Corp across 12 annual periods. Also explore Blueprint Medicines Corp equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Blueprint Medicines Corp (2013–2024)
Year-by-year debt coverage analysis for Blueprint Medicines Corp. For market capitalisation and broader financial context, see Blueprint Medicines Corp stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.22x | $-192.59 Million | $881.15 Million | ▲ +54.0% |
| 2023 | -0.48x | $-436.85 Million | $918.64 Million | ▲ +20.9% |
| 2022 | -0.60x | $-502.28 Million | $835.23 Million | ▲ +43.3% |
| 2021 | -1.06x | $-298.65 Million | $281.49 Million | ▼ -168.1% |
| 2020 | 1.56x | $387.04 Million | $248.31 Million | ▲ +236.4% |
| 2019 | -1.14x | $-278.01 Million | $243.34 Million | ▲ +20.9% |
| 2018 | -1.44x | $-175.01 Million | $121.11 Million | ▼ -10.6% |
| 2017 | -1.31x | $-119.86 Million | $91.77 Million | ▼ -271.5% |
| 2016 | -0.35x | $-24.51 Million | $69.72 Million | ▲ +61.2% |
| 2015 | -0.91x | $-31.68 Million | $34.92 Million | ▲ +62.9% |
| 2014 | -2.44x | $-35.40 Million | $14.50 Million | ▲ +27.7% |
| 2013 | -3.38x | $-19.02 Million | $5.63 Million | — |